Annual CNS Overview Issue Released by NeuroPerspective
(firmenpresse) - CARDIFF, CA -- (Marketwire) -- 01/04/12 -- NeuroPerspective has released its January issue, which reviews 2011 and previews 2012 for the CNS therapeutics sector.
The review of 2011 includes NeuroPerspective's annual awards, in such categories as:
Best and Worst News of 2011
Best and Worst Performances by a CEO
The Lazarus Award
Best VC Funding Deal
Highlights and Lowlights for the year are discussed, with particular attention devoted to: Drugs with nicotinic mechanisms, including those from Targacept (NASDAQ: TRGT) and EnVivo Pharmaceuticals; the maturation of the MS therapeutics sector; BioTie's aggressive growth strategy; the temporarily popular fad of industry/academic collaboration; Alexza Pharmaceuticals (NASDAQ: ALXA) and the FDA; NeuroSearch's shrinkage; and Geron's unconscionable exit from their long-awaited spinal cord injury trial.
Capsule summaries of events and 2012 prospects for 100 CNS-oriented companies are included in the January issue.
Other features include: Assessments of the CNS area funding and partnering environments during 2011 ('Starvation Rations in the NeuroGulag'), a year which saw a decrease in resources of 23% from 2010; a wishlist for the sector; reasons for optimism about the profile of CNS therapeutics in the pharma environment; and this month's Company Review, featuring BioTie.
NeuroPerspective is the independent, monthly review of the neurotherapeutics area. A one-year subscription is US$2200, delivered as a pdf via email. A three month trial subscription is US$700.
NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroPerspective (formerly NeuroInvestment ) since 1995; the Private CNS Company Review since 2003; and CNS Therapeutics and Licensing, an annual compendium of all CNS R&D programs, since 2007. NI Research has developed an unmatched information base regarding both publicly and privately held neurotherapeutics companies, and offers M&A/licensing consultation services.
Contact:
NI Research
P.O. Box 1028
Cardiff, CA 92007
760.230.2581
E-mail:
Website:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.01.2012 - 12:00 Uhr
Sprache: Deutsch
News-ID 100873
Anzahl Zeichen: 0
contact information:
Town:
CARDIFF, CA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 253 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Annual CNS Overview Issue Released by NeuroPerspective"
steht unter der journalistisch-redaktionellen Verantwortung von
NeuroPerspective (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
